

Table 44: Summary of Overall Flushing Events, MFSS

Biogen ASSURE 109MS406 (Interim)

Page 1 of 20

Summary of overall flushing events, MFSS

Overall flushing events

	ASA placebo BID (N=81)	ASA 75 mg QAM (N=80)	ASA 150 mg BID (N=80)
Weeks 5 - 8 Combined			
Numbers of subjects evaluable	71 (87.7%)	70 (87.5%)	70 (87.5%)
Numbers of subjects with overall side effects	57 (80.3%)	58 (82.9%)	59 (84.3%)
Difference in percentage		2.6 (6.53)	4.0 (6.42)
95% CI [1]		-10.2 , 15.4	-8.6 , 16.6
Weeks 9 - 12 Combined			
Numbers of subjects evaluable	68 (84.0%)	65 (81.3%)	65 (81.3%)
Numbers of subjects with overall side effects	45 (66.2%)	45 (69.2%)	51 (78.5%)
Difference in percentage		3.1 (8.10)	12.3 (7.68)
95% CI [1]		-12.8 , 18.9	-2.8 , 27.3

[1] Two sided 95% CI of difference in proportions was constructed based on the normal approximation